A number of other equities analysts have also recently commented on the company. Zacks Investment Research raised Sanofi from a sell rating to a hold rating in a report on Monday, July 25th. Citigroup Inc. reissued a neutral rating on shares of Sanofi in a report on Tuesday, June 28th. Jefferies Group reissued a hold rating on shares of Sanofi in a report on Wednesday, September 14th. JPMorgan Chase & Co. reissued an underweight rating on shares of Sanofi in a report on Thursday, September 15th. Finally, TheStreet raised Sanofi from a hold rating to a buy rating in a report on Wednesday, July 27th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $60.50.
Shares of Sanofi (NYSE:SNY) opened at 38.53 on Friday. The company’s 50 day moving average price is $38.79 and its 200-day moving average price is $40.45. The company has a market capitalization of $99.18 billion, a price-to-earnings ratio of 21.36 and a beta of 0.98. Sanofi has a 52 week low of $37.41 and a 52 week high of $51.88.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Boston Partners raised its position in shares of Sanofi by 10,203.3% in the second quarter. Boston Partners now owns 7,402,009 shares of the company’s stock valued at $309,774,000 after buying an additional 7,330,168 shares during the last quarter. Dodge & Cox raised its position in shares of Sanofi by 7.2% in the first quarter. Dodge & Cox now owns 53,530,129 shares of the company’s stock valued at $2,149,770,000 after buying an additional 3,615,056 shares during the last quarter. Hamlin Capital Management LLC acquired a new position in shares of Sanofi during the second quarter valued at $56,725,000. Hotchkis & Wiley Capital Management LLC raised its position in shares of Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock valued at $478,434,000 after buying an additional 1,267,118 shares during the last quarter. Finally, Senzar Asset Management LLC acquired a new position in shares of Sanofi during the second quarter valued at $46,173,000. Institutional investors own 9.42% of the company’s stock.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.